Charles River Laboratories Expands Access to AAALAC-Accredited, Turnkey Research Space in Key Markets
01 Agosto 2023 - 9:00AM
Business Wire
New CRADL spaces in Seattle and Philadelphia
will provide flexible vivarium space for biopharmaceutical
industry
Charles River Laboratories International, Inc. (NYSE: CRL)
announced the planned openings of Charles River Accelerator and
Development Lab (CRADL®) locations in Seattle and Philadelphia,
expanding contract vivarium space for the biopharmaceutical
industry.
CRADL Seattle is opening this September as Charles River's most
recent investment in Seattle, addressing the demand for more
flexible vivarium space as well as on-demand in vivo study support
services. CRADL’s first Seattle facility opened in 2021, in
response to the city’s growing position as a key life sciences hub
with significant start-up and entrepreneurial growth.
In October, CRADL Philadelphia will open in uCity Square to
support Philadelphia’s growth as a life sciences biohub.
Philadelphia has established itself as a leader in cell therapy,
gene therapy, and gene editing, with a high number of gene therapy
development companies developing in the Greater Philadelphia
region. With a robust and diverse life sciences community, the
CRADL facility will provide much needed research space to support
the area’s continued growth.
By offering on-demand facilities, both emerging and established
biopharmaceutical companies and research institutions can quickly
start new in vivo studies, accelerating the preclinical research
stages. Each CRADL site provides flexible spaces, animal husbandry,
and vivarium management, allowing scientists to focus on research,
stay agile, and remain financially unencumbered as they scale.
Expanding Access and Expertise to Global Ecosystems through
CRADL
With the addition of these two new sites, the CRADL Vivarium
Network operates 32 vivaria, and over 410,000 square feet of
turnkey rental capacity in key biohubs, including Massachusetts,
California, Washington, Shanghai, Chengdu, London, Illinois, and
now Pennsylvania. Recently, CRADL vivaria in both Shanghai and
London received AAALAC accreditation, joining the Company's North
American locations in achieving recognition of a commitment to
operating at the highest standard of animal welfare. This network
supports the growth of the entire biotech ecosystem in each city,
allowing researchers to rapidly engage in their research while
maintaining the flexibility to relocate or co-locate, knowing they
will have reliable, high-quality facilities nearby.
Approved Quotes
- “Both Seattle and Philadelphia are emerging as cities with
significant biopharmaceutical communities. CRADL’s unique offering
of contract vivarium space combined with Charles River’s extensive
preclinical network, supports clients in starting projects quickly,
without the costly burden of building infrastructure.” –Colin Dunn,
Ph.D., Corporate Senior Vice President, Global Research Models
& Services, Charles River
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230801942391/en/
Investors: Todd Spencer Corporate Vice President,
Investor Relations 781.222.6455 todd.spencer@crl.com
Media: Amy Cianciaruso Corporate Vice President, Chief
Communications Officer 781.222.6168 amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Charles River Laboratories (NYSE:CRL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024